Charles River Laboratories International (CRL) Common Equity (2009 - 2025)

Charles River Laboratories International (CRL) has reported Common Equity for 17 consecutive years, with $3.2 billion the latest figure, recorded in Q4 2025.

• In Q4 2025, Common Equity fell 8.72% year-over-year to $3.2 billion; the TTM figure through Dec 2025 stood at $3.2 billion (down 8.72% YoY), while the FY2025 annual figure was $3.2 billion, down 8.72% from the prior year.
• Common Equity came in at $3.2 billion for Q4 2025 at Charles River Laboratories International, down from $3.4 billion in the prior quarter.
• The five-year high for Common Equity was $3.8 billion in Q3 2024, with the low at $2.2 billion in Q1 2021.
• Average Common Equity over 5 years is $3.1 billion, with a median of $3.2 billion recorded in 2025.
• Across the five-year window, Common Equity jumped 32.25% in 2021 and decreased 12.23% in 2025, its largest moves.
• Year by year, Common Equity stood at $2.5 billion in 2021, then increased by 17.41% to $3.0 billion in 2022, then rose by 20.84% to $3.6 billion in 2023, then slipped by 3.76% to $3.5 billion in 2024, then decreased by 8.72% to $3.2 billion in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $3.2 billion, $3.4 billion, and $3.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.